Back To: Home

Our 2017 Media Kit is now available
Our 2018 Media Kit is now available
Your gateway to the latest oncology news, trends and resources
Inside this issue:
September 2017
Exscientia shares artificial intelligence capacity with top pharmaceutical partner...
by Rachel Flehinger
September 2017
Merck KGaA uses Genedata functionalities to scale up bispecific antibody discovery programs...
by Ilene Schneider
September 2017
Results support therapeutic potential of the pan-PPAR agonist for the treatment of NASH...
by Mel J. Yeates
September 2017
Is our arsenal evolving quickly enough to match its protean foe?...
by Randall C Willis
Extra September Content Online
The September 2017 issue offered four bonus items in terms of commentary and special insight in addition to that issue's guest commentary and our regular Out of Order column, three of which are only available online:
Bonus Guest Commentary
"Affinity and beyond--Assessing the alternatives to therapeutic antibodies"
New technological developments that would benefit from a new breed of affinity binders include antibody-drug conjugates that link cytotoxic drugs to targeting binders, bi-specific affinity molecules that concurrently target multiple biological pathways and new affinity reagents for the evolution of in-vivo imaging. These technologies have the potential to fundamentally reshape the industry, not only offering essential healthcare cost savings, but also to provide new medicines with improved safety and efficacy for patients. (Click here to read)
Q&A: In-vivo models of infectious disease
We speak to Adriano Flora, associate director of the Scientific Program Management Group at Taconic Biosciences (click here to read)
Patent Docs: Federal Circuit Loosens Requirements for Finding Inequitable Conduct
Earlier this month, the Federal Circuit affirmed a decision by a district court that the patent at issue before it had been obtained through inequitable conduct.  However, contrary to prevailing standards the district court used litigation misconduct rather than malfeasance during patent prosecution to justify its decision, raising fears that lawyers involved in obtaining patents for their clients may be found liable for conduct of (other) lawyers representing their clients in litigation. (Click here to read)
CRISPR commentary: Two barriers to CRISPR’s success and how they can be overcome
This item, part of our Special Focus on CRISPR for September, did appear in the issue, but doesn't show up as an individual commentary online. Read the CRISPR feature here to check it out.


Editor's Focus:
September 2017
There seems to be an assumption that if something is statistically significant, it is medically relevant. The corollary would imply that something determined not statistically significant is therefore not medically relevant. But is this true? And medically relevant for whom? .. [ more ]
by Randall C Willis

September 2017
Can the pharma world better select new molecules that will have a greater than a 1:10,000 chance of progressing through development and making a successful, safe, marketed product?.. [ more ]
by Guy Webber of Envigo

September 2017
A look at the bonuses to be found on the DDNews websites with our Editconnect codes.. [ more ]
by Jeffrey Bouley

Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by Offenberger & White.